

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6255304

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ARES TRADING S.A.	04/19/2018
RECEIVING PARTY DATA	
Name:	FRESENIUS KABI DEUTSCHLAND GMBH
Street Address:	ELSE KROENER STRASSE 1
City:	BAD HOMBURG
State/Country:	GERMANY
Postal Code:	61352
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16990954
CORRESPONDENCE DATA	
Fax Number:	(617)523-1231
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 570-1000
Email:	us-patentbos@goodwinlaw.com, tayube@goodwinlaw.com, ckomm@goodwinlaw.com
Correspondent Name:	GOODWIN PROCTER LLP
Address Line 1:	100 NORTHERN AVENUE
Address Line 2:	IP DOCKETING DEPT./7TH FL
Address Line 4:	BOSTON, MASSACHUSETTS 02210
ATTORNEY DOCKET NUMBER:	FRK-002C2
NAME OF SUBMITTER:	CRYSTAL A. KOMM
SIGNATURE:	/Crystal A. Komm/
DATE SIGNED:	08/18/2020
Total Attachments: 3	
source=Assignment by Ares to Fresenius#page1.tif	
source=Assignment by Ares to Fresenius#page2.tif	
source=Assignment by Ares to Fresenius#page3.tif	

ASSIGNMENT OF PATENT RIGHTS

WHEREAS, Ares Trading S.A. ("ASSIGNOR"), a corporation organized under and pursuant to the laws of Switzerland having a business address at Zone Industrielle de L'Ouriettaz, CH-1170 Aubonne, Switzerland, owns an undivided interest in the inventions as described and set forth in the patent applications listed on Schedule A attached hereto (hereinafter, the "Patent Applications");

WHEREAS, Fresenius Kabi Deutschland GmbH ("ASSIGNEE"), a corporation organized under and pursuant to the laws of Germany having a business address at Else-Kröner-Straße 1, Bad Homburg, 61352 Germany, is desirous of acquiring the entirety of ASSIGNOR's undivided interest in said inventions and said Patent Applications and in any Letters Patent which may be granted from the same and/or claim priority to said Patent Applications;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR by these presents does hereby sell, assign and transfer unto said ASSIGNEE, its successors, and assigns, the entirety of ASSIGNOR's undivided interest in and to said inventions, said Patent Applications, and any Letters Patent which may hereafter be granted on the same or claim priority thereto under United States law or international convention in the United States and all countries throughout the world, including but not limited to non-provisionals, continuations, continuations-in-part, divisionals, reissues, reexaminations, extensions, and substitutions thereof, said interest to be held and enjoyed by said ASSIGNEE as fully and exclusively as it would have been held by said ASSIGNOR had this assignment and transfer not been made, to the full extent and term of any Letters Patent; and

ASSIGNOR hereby assigns any and all claims and causes for action for infringement of such Patent Applications, and any Letters Patent which may hereafter be granted on the same or claim priority to said Patent Applications which have accrued up to and including the date of this Assignment, including all rights to recover damages; and

ASSIGNOR hereby covenants that it has the full right, power and authority to convey its entire right, title and interest in and to the inventions and Patent Applications and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment; and

ASSIGNOR further covenants and agrees to provide ASSIGNEE, upon ASSIGNEE's request, all pertinent facts and documents relating to the inventions and Patent Applications as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, administrative proceeding, or litigation related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required for the prosecution of said Patent Applications and for the maintenance or enforcement of any Letters Patent which may hereafter be granted on the same or claim priority to said Patent Applications; and

ASSIGNOR further covenants and agrees that at the request of ASSIGNEE, ASSIGNOR will sign all lawful papers, make all rightful oaths, and execute any continuations, divisionals, continuation-in-part applications, reexaminations, reissues, and extension applications that are deemed necessary or desirable to ASSIGNEE, and will execute any additional documents necessary to effectuate this Assignment and to vest title to said inventions and Patent Applications in said ASSIGNEE, or ASSIGNEE's successors and assigns.

IN TESTIMONY WHEREOF, ASSIGNOR and ASSIGNEE have caused their respective duly authorized representatives to execute this Assignment.

ARES TRADING S.A.
By: *Edsca Von Ballmoos*
Printed Name: Edsca VON BALLMOOS
Title: Authorized Representative
Date: 19. 04. 2018

ARES TRADING S.A.
By: *Luigia Bocola*
Printed Name: Luigia Bocola
Title: Authorized Representative
Date: 19. 04. 2018

Witnessed by: *Sharon Mutawe*
Printed Name: Sharon Mutawe
Address: 244 Chemin de la Chenaille 1293 Bellevue, Switzerland
Date: 19. 04. 2018

Witnessed by: *Rafaela Perroni*
Printed Name: RAFAELA PERRONI
Address: 185 RUE DE L'OPIDVII-OMIS RIVIERE DES BOIS - FRANCE
Date: 19/04/2018

FRESENIUS KABI DEUTSCHLAND GMBH
By: *S. M.*
Printed Name: Dr. Corinna Sundermann
Title: Senior Vice President
Date: 25. April 2018

Witnessed by: *S. Duschner*
Printed Name: Dr. Sabrina Duschner
Address: WESTPHALISCHE WERKE AG 16 BIELEFELD, GERMANY
Date: 25 April 2018

SCHEDULE A

<u>Title</u>	<u>Docket No.</u>	<u>Country</u>	<u>Application Number</u>
Liquid Pharmaceutical Composition	ATR-001	United States	15/313,470
Liquid Pharmaceutical Composition	ATR-002	United States	15/313,480
Liquid Pharmaceutical Composition	ATR-003	United States	15/313,487
Liquid Pharmaceutical Composition	ATR-005	United States	15/548,730
Induction Dosing Regimen	ATR-006	United States	15/564,677

ACTIVE/86612749.1